ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

RZLT Rezolute Inc

3.31
0.34 (11.45%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Rezolute Inc RZLT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.34 11.45% 3.31 17:53:39
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.06 2.98 3.38 3.31 2.97
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
23/4/202407:00GLOBEPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024..
11/3/202416:03EDGAR2Form 8-K - Current report
11/3/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202406:30GLOBERezolute Reports Validation of the Potential Use of RZ358..
27/2/202407:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202416:00EDGAR2Form 8-K - Current report
21/2/202410:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202416:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202415:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/2/202415:10EDGAR2Form 8-K - Current report
13/2/202415:05GLOBERezolute Reports Second Quarter Fiscal 2024 Results and..
29/1/202416:15EDGAR2Form 8-K - Current report
25/1/202411:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202411:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202411:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202411:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202407:00GLOBERezolute Expands Leadership Team with Appointment of Daron..
23/1/202407:00GLOBERezolute Receives Innovation Passport Designation from the..
14/12/202315:01EDGAR2Form 8-K - Current report
14/12/202307:00GLOBERezolute Initiates Phase 3 Clinical Study for RZ358 in..
13/12/202307:00GLOBERezolute Completes Enrollment of its Phase 2 Study in..
29/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
22/11/202316:16EDGAR2Form S-3/A - Registration statement under Securities Act of..
22/11/202315:35EDGAR2Form 8-K - Current report
17/11/202307:00GLOBERezolute to Participate in BTIG’s 3rd Annual Ophthalmology..
15/11/202308:08EDGAR2Form S-3 - Registration statement under Securities Act of..
13/11/202315:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202315:13EDGAR2Form 8-K - Current report
13/11/202315:05GLOBERezolute Reports First Quarter Fiscal 2024 Results
18/10/202315:30EDGAR2Form 8-K - Current report
17/10/202307:00GLOBERezolute Receives Priority Medicines (PRIME) Eligibility..
13/10/202315:47EDGAR2Form 8-K - Current report
13/10/202315:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/10/202307:00GLOBERezolute Announces Further Evidence of RZ358’s Efficacy in..
14/9/202315:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
14/9/202315:10EDGAR2Form 8-K - Current report
14/9/202315:05GLOBERezolute Reports Full Year Fiscal 2023 Results and..
06/9/202306:00GLOBERezolute to Participate in Upcoming Investor Conferences in..
06/7/202310:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/6/202315:05GLOBERezolute to Initiate a Pivotal Phase 3 Study of RZ358 in..
11/5/202315:05GLOBERezolute Reports Third Quarter Fiscal 2023 Results and..

Su Consulta Reciente

Delayed Upgrade Clock